Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|44-48

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 44-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

By Stroppa Elisa   Bertuzzi Alexia   Comite Gabriele   Mussi Chiara   Lutman Romano   Barbato Alfredo   Santoro Armando  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 834-838

Springer Publishing Company

Access to resources Recommend Favorite

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 4006-4007

Blackwell Publishing

Access to resources Recommend Favorite

Magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 4005-4006

Blackwell Publishing

Access to resources Recommend Favorite

Rituximab added to CHOP chemotherapy shows promise as a treatment for HIV-associated non-Hodgkin's lymphoma (NHL)

By  

Inpharma, Vol. 1, Iss. 1551, 2006-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite